↓ Skip to main content

NeuroPsychopharmacotherapy

Overview of attention for book
Cover of 'NeuroPsychopharmacotherapy'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Pharmacokinetic and Pharmacodynamic Principles
  3. Altmetric Badge
    Chapter 2 Neurobiological Principles: Psycho-Neuro-Immuno-Endocrinology
  4. Altmetric Badge
    Chapter 3 Experimental Psychopharmacology
  5. Altmetric Badge
    Chapter 4 Randomized Controlled Trials and the Efficacy of Psychotropic Medications
  6. Altmetric Badge
    Chapter 5 Psychopathology: Rating Scales for the Assessment of Mental Status
  7. Altmetric Badge
    Chapter 6 Compliance and Psychoeducation
  8. Altmetric Badge
    Chapter 8 Adverse Drug Reactions, Intoxications and Interactions of Neuropsychotropic Medications
  9. Altmetric Badge
    Chapter 9 Pharmacovigilance
  10. Altmetric Badge
    Chapter 10 Xenobiotic Interactions in Psychopharmacotherapy: Classification and Handling
  11. Altmetric Badge
    Chapter 12 Psychopharmacology: A Brief Overview of Its History
  12. Altmetric Badge
    Chapter 14 Causal Inference Methods in Pharmacoepidemiology
  13. Altmetric Badge
    Chapter 16 Neuropsychopharmacotherapy: Guidelines
  14. Altmetric Badge
    Chapter 17 Health Economics for Neuropsychological Diseases in China
  15. Altmetric Badge
    Chapter 20 Nutrition in Brain Aging: Its Relevance to Age-Associated Neurodegeneration
  16. Altmetric Badge
    Chapter 21 Historical Overview of Psychiatric Diagnostics in Japan
  17. Altmetric Badge
    Chapter 22 Neuropsychopharmacotherapy: Differential Dose Regimes in China
  18. Altmetric Badge
    Chapter 23 Neuropsychopharmacotherapy: Complementary Treatments
  19. Altmetric Badge
    Chapter 24 Antidepressants: Definition, Classification, Guidelines
  20. Altmetric Badge
    Chapter 26 Antidepressants: Pharmacology and Biochemistry
  21. Altmetric Badge
    Chapter 28 Antidepressants: Course and Duration of Therapy, Withdrawal Syndromes, and Resistance to Therapy
  22. Altmetric Badge
    Chapter 29 Antidepressants: Indications, Contraindications, Interactions, and Side Effects
  23. Altmetric Badge
    Chapter 31 Agomelatine and Depressions
  24. Altmetric Badge
    Chapter 35 Mood Stabilizer: Definition
  25. Altmetric Badge
    Chapter 36 Mood Stabilizers: Classification, Indications and Differential Indications
  26. Altmetric Badge
    Chapter 37 Mood Stabilizers: Pharmacology and Biochemistry
  27. Altmetric Badge
    Chapter 39 Mood Stabilizers: Course and Duration of Therapy, Withdrawal Syndromes, and Resistance to Therapy
  28. Altmetric Badge
    Chapter 40 Mood Stabilizers: Side Effects, Contraindications, and Interactions
  29. Altmetric Badge
    Chapter 43 Mood Stabilizers: Asenapine
  30. Altmetric Badge
    Chapter 44 Mood Stabilizers: Carbamazepine
  31. Altmetric Badge
    Chapter 45 Mood Stabilizers: Lithium
  32. Altmetric Badge
    Chapter 46 Mood Stabilizers: Olanzapin
  33. Altmetric Badge
    Chapter 47 Mood Stabilizers: Quetiapine
  34. Altmetric Badge
    Chapter 48 Mood Stabilizers: Risperidone for Treating Bipolar Disorders in Adults
  35. Altmetric Badge
    Chapter 49 Mood Stabilizers: Valproate
  36. Altmetric Badge
    Chapter 51 Antipsychotics/Neuroleptics: Definition, Classification, Indications and Differential Indications
  37. Altmetric Badge
    Chapter 52 Antipsychotics/Neuroleptics: Pharmacology and Biochemistry
  38. Altmetric Badge
    Chapter 54 Antipsychotics/Neuroleptics: Course and Duration of Therapy, Withdrawal Symptoms, Resistance to Therapy, Side Effects, and Contraindications
  39. Altmetric Badge
    Chapter 57 Amisulpride and Sulpiride in the Treatment of Psychosis
  40. Altmetric Badge
    Chapter 59 Tranquilizers/Anxiolytics: Definition, Indications, Contraindications, and Treatment
  41. Altmetric Badge
    Chapter 61 Tranquilizers/Anxiolytics: Pharmacology and Biochemistry of Anxiolytic Drugs Acting via GABAergic Mechanisms
  42. Altmetric Badge
    Chapter 71 Hypnotics: Pharmacology
  43. Altmetric Badge
    Chapter 77 Hypnotics: Guidelines and Current References
  44. Altmetric Badge
    Chapter 79 Anti-dementia Medications: Classification, Indications, and Differential Indications
  45. Altmetric Badge
    Chapter 81 Amitriptyline and Depressions
  46. Altmetric Badge
    Chapter 82 Amoxapine and Depressions
  47. Altmetric Badge
    Chapter 83 Bupropion and Depressions
  48. Altmetric Badge
    Chapter 92 Ginseng and Ginsenosides in Depression
  49. Altmetric Badge
    Chapter 93 Hypericum and Depression
  50. Altmetric Badge
    Chapter 98 Monoamine Oxidase Inhibitors in Depressive Disorders
  51. Altmetric Badge
    Chapter 100 Mianserine and Depressions
  52. Altmetric Badge
    Chapter 102 Mirtazapine and Depressions
  53. Altmetric Badge
    Chapter 111 Trazodone and Depression
  54. Altmetric Badge
    Chapter 113 Vilazodone and Depressions
  55. Altmetric Badge
    Chapter 114 Vortioxetine and Depressions
  56. Altmetric Badge
    Chapter 117 Guidelines on Mood Stabilizers
  57. Altmetric Badge
    Chapter 118 Cariprazine in the Treatment of Psychosis
  58. Altmetric Badge
    Chapter 127 Haloperidol in the Treatment of Psychosis
  59. Altmetric Badge
    Chapter 159 Tranquilizer/Anxiolytics: Lavender Oil
  60. Altmetric Badge
    Chapter 160 Tranquilizer/Anxiolytics: Buspirone
  61. Altmetric Badge
    Chapter 161 Tranquilizer/Anxiolytics: Gabapentin
  62. Altmetric Badge
    Chapter 162 Tranquilizer/Anxiolytics: Mexazolam
  63. Altmetric Badge
    Chapter 163 Tranquilizer/Anxiolytics: Antidepressants
  64. Altmetric Badge
    Chapter 166 Tranquilizer/Anxiolytics: Pregabalin
  65. Altmetric Badge
    Chapter 167 Tranquilizer/Anxiolytics: Tandospirone
  66. Altmetric Badge
    Chapter 192 Anti-dementia Medications: Pharmacology and Biochemistry
  67. Altmetric Badge
    Chapter 194 Anti-dementia Medications: Course and Duration of Therapy and Withdrawal Syndromes
  68. Altmetric Badge
    Chapter 195 Anti-dementia Medications and Anti-Alzheimer’s Disease Drugs: Side Effects, Contraindications, and Interactions
  69. Altmetric Badge
    Chapter 200 Memantine for Treatment of Dementia
  70. Altmetric Badge
    Chapter 213 Definition and Classification of Parkinsonian Drugs
  71. Altmetric Badge
    Chapter 215 Clinical Aspects of the Pharmacology and Biochemistry of Drugs for the Treatment of Motor Symptoms of Parkinson’s Disease
  72. Altmetric Badge
    Chapter 216 Parkinsonian Drugs: Indications
  73. Altmetric Badge
    Chapter 217 Course and Duration of Therapy with Parkinsonian Drugs and Withdrawal Syndromes
  74. Altmetric Badge
    Chapter 218 Side Effects, Contraindications, and Drug-Drug Interactions in the Use of Antiparkinsonian Drugs
  75. Altmetric Badge
    Chapter 219 Drugs in the Treatment of Dystonia, Multisystem Atrophy, and Non-Parkinson Tremor
  76. Altmetric Badge
    Chapter 220 Amantadine for Treating Parkinson’s Disease
  77. Altmetric Badge
    Chapter 221 Trihexyphenidyl, Biperiden, and Other Anticholinergics in the Treatment of Parkinson’s Disease
  78. Altmetric Badge
    Chapter 222 Bromocriptine for Treating Parkinson’s Disease
  79. Altmetric Badge
    Chapter 223 Cabergoline in the Treatment of Parkinson’s Disease
  80. Altmetric Badge
    Chapter 224 Piroheptine for Treating Parkinson
  81. Altmetric Badge
    Chapter 225 Levodopa Therapy for the Treatment of Parkinson’s Disease
  82. Altmetric Badge
    Chapter 228 Droxidopa for the Treatment of Parkinson’s Disease
  83. Altmetric Badge
    Chapter 229 Levodopa/Carbidopa Intestinal Gel in Parkinson’s Disease
  84. Altmetric Badge
    Chapter 230 Entacapone/Tolcapone/Opicapone for Treating Parkinson’s Disease
  85. Altmetric Badge
    Chapter 232 Pergolide in the Treatment of Parkinson’s Disease
  86. Altmetric Badge
    Chapter 233 Pramipexole for Treating Parkinson’s Disease
  87. Altmetric Badge
    Chapter 234 From Anti-Parkinson’s Drug Rasagiline to Novel Multitarget Iron Chelators with Acetylcholinesterase and Monoamine Oxidase Inhibitory and Neuroprotective Properties for Alzheimer’s Disease
  88. Altmetric Badge
    Chapter 235 Ropinirole in the Treatment of Parkinson’s Disease
  89. Altmetric Badge
    Chapter 236 Safinamide for Treating Parkinson’s Disease
  90. Altmetric Badge
    Chapter 237 Selegiline for Treating Parkinson’s Disease
  91. Altmetric Badge
    Chapter 238 Monoamine Oxidase Inhibitor (MAO-I)-Mediated Neuroprotection for Treating Parkinson’s Disease
  92. Altmetric Badge
    Chapter 242 Zonisamide for Treating Parkinson’s Disease
  93. Altmetric Badge
    Chapter 252 Pharmacotherapy of Personality Disorders
  94. Altmetric Badge
    Chapter 254 Pharmacotherapy of ADHD in Adults
  95. Altmetric Badge
    Chapter 255 Psychopharmacotherapy of Sexual Disorders
  96. Altmetric Badge
    Chapter 256 Therapy of Withdrawal Syndromes, Addiction Disorders, and Substitution Therapies
  97. Altmetric Badge
    Chapter 257 Psychopharmacotherapy in Patients with Tics and Other Motor Disorders
  98. Altmetric Badge
    Chapter 258 Neuropsychopharmacotherapy: Emergency Psychiatry
  99. Altmetric Badge
    Chapter 259 Neuropharmacology of Dementias
  100. Altmetric Badge
    Chapter 267 Effects of Psychopharmacological Medicines upon Driving Ability
  101. Altmetric Badge
    Chapter 268 Psychopharmacological Agents During Pregnancy and Nursing
  102. Altmetric Badge
    Chapter 269 Psychopharmacotherapy in Aged Patients
  103. Altmetric Badge
    Chapter 270 Neuropsychopharmacotherapy in Children and Adolescents
  104. Altmetric Badge
    Chapter 271 Forced Migration and Mental Health Care
  105. Altmetric Badge
    Chapter 274 Anti-convulsant Agents: Definition and Indication
  106. Altmetric Badge
    Chapter 275 Anti-convulsant Agents: Ethosuximide and Methsuximide
  107. Altmetric Badge
    Chapter 278 Anti-convulsant Agents: Vigabatrin
  108. Altmetric Badge
    Chapter 279 Anti-convulsant Agents: Beginning, Maintenance, Pharmacoresistance, Duration of Therapy, and Withdrawal – Adults
  109. Altmetric Badge
    Chapter 280 Anti-convulsant Agents: Principal Considerations on Effectiveness, Side Effects, and Interactions
  110. Altmetric Badge
    Chapter 283 Anti-dementia Medications: Specific Agents
  111. Altmetric Badge
    Chapter 287 Lisuride: An 8-Alpha-Ergoline with Ergot Antagonistic Properties
  112. Altmetric Badge
    Chapter 288 Treatment of Parkinson’s Disease: Early, Late, and Combined
  113. Altmetric Badge
    Chapter 290 Parkinsonian Drugs in China
  114. Altmetric Badge
    Chapter 291 German Guidelines for the Use of Parkinsonian Drugs
  115. Altmetric Badge
    Chapter 293 Anti-convulsant Agents: Rufinamide
  116. Altmetric Badge
    Chapter 294 Anti-convulsant Agents: Carbamazepine, Oxcarbazepine, and Eslicarbazepine Acetate
  117. Altmetric Badge
    Chapter 296 Anti-convulsant Agents: Stiripentol
  118. Altmetric Badge
    Chapter 297 Anti-convulsant Agents: Felbamate
  119. Altmetric Badge
    Chapter 299 Anti-convulsant Agents: Gabapentin and Pregabalin
  120. Altmetric Badge
    Chapter 300 Anti-convulsant Agents: Lamotrigine
  121. Altmetric Badge
    Chapter 301 Anti-convulsant Agents: Levetiracetam and Brivaracetam
  122. Altmetric Badge
    Chapter 302 Anti-convulsant Agents: Phenobarbital and Primidone
  123. Altmetric Badge
    Chapter 303 Anti-convulsant Agents: Phenytoin and Fosphenytoin
  124. Altmetric Badge
    Chapter 304 Anti-convulsant Agents: Potassium Bromide
  125. Altmetric Badge
    Chapter 305 Anti-convulsant agents: Cortisone and Adrenocorticotropic Hormone (ACTH)
  126. Altmetric Badge
    Chapter 306 Anti-convulsant Agents: Everolimus
  127. Altmetric Badge
    Chapter 307 Anti-convulsant Agents: Sulthiame
  128. Altmetric Badge
    Chapter 308 Anti-convulsant Agents: Topiramate
  129. Altmetric Badge
    Chapter 309 Anti-convulsant Agents: Valproic Acid
  130. Altmetric Badge
    Chapter 310 Anti-convulsant Agents: Zonisamide
  131. Altmetric Badge
    Chapter 311 Guidelines on Anti-convulsant Agents
  132. Altmetric Badge
    Chapter 315 Psychostimulants: Primary and Secondary Indications
  133. Altmetric Badge
    Chapter 319 Efficacy of Amphetamines, Methylphenidate, and Modafinil in the Treatment of Mental Disorders
  134. Altmetric Badge
    Chapter 324 Stimulants: Definition, Pharmacology, Indications, Side Effects, and Treatment Strategies
  135. Altmetric Badge
    Chapter 340 Pharmacology of Alcohol and Alcohol Use Disorder
  136. Altmetric Badge
    Chapter 342 Disulfiram and Cyanamide
  137. Altmetric Badge
    Chapter 350 Agents for Treatment of Withdrawal and Dependency: Varenicline
  138. Altmetric Badge
    Chapter 354 Parkinsonian Drugs: Guidelines for Japan
  139. Altmetric Badge
    Chapter 356 Guidelines for the Use of Parkinsonian Drugs in Canada
  140. Altmetric Badge
    Chapter 357 Guidelines for the Use of Parkinsonian Drugs (in USA)
  141. Altmetric Badge
    Chapter 358 Guidelines for Therapeutic Management of Parkinson’s Disease in China
  142. Altmetric Badge
    Chapter 359 Parkinsonian Toxins: From MPTP to Endogenous Neurotoxins
  143. Altmetric Badge
    Chapter 360 Apomorphine for the Treatment of Parkinson’s Disease
  144. Altmetric Badge
    Chapter 361 Istradefylline for Treating Parkinson’s Disease
  145. Altmetric Badge
    Chapter 362 Mazaticol for Treating Parkinson
  146. Altmetric Badge
    Chapter 364 Rotigotine for Treating Parkinson’s Disease
  147. Altmetric Badge
    Chapter 365 Neurobiological Principles: Neurotransmitters
  148. Altmetric Badge
    Chapter 366 Neuropsychopharmacotherapy and the Differential Diagnostic Approaches in China
  149. Altmetric Badge
    Chapter 367 Neuro-psychopharmacotherapy and the Differential Diagnostic Approaches in Europe
  150. Altmetric Badge
    Chapter 368 Mood Stabilizers: Lamotrigine
  151. Altmetric Badge
    Chapter 369 Antidepressants: Molecular Aspects of SSRIs
  152. Altmetric Badge
    Chapter 370 Anti-convulsive Drug Use in Status Therapy: Adults
  153. Altmetric Badge
    Chapter 371 Anti-convulsant Agents: Beginning and Duration of Therapy, Withdrawal, and Resistance – Children
  154. Altmetric Badge
    Chapter 373 Anti-convulsive Drug Use in Status Treatment in Children
  155. Altmetric Badge
    Chapter 374 Anti-convulsant Agents: Acute Drug Therapy Outside Status Epilepticus
  156. Altmetric Badge
    Chapter 375 Anti-convulsant Drugs and Cognition
  157. Altmetric Badge
    Chapter 377 Rational Antiepileptic Treatment in Childhood
  158. Altmetric Badge
    Chapter 379 Anti-convulsant Drugs: Differential Indications – Neuropathic Pain and Migraine
  159. Altmetric Badge
    Chapter 380 Ethical Issues in Neuropsychopharmacotherapy: US Perspective
  160. Altmetric Badge
    Chapter 381 Pharmacoeconomics
  161. Altmetric Badge
    Chapter 383 Cognitive Enhancement and American Constitutional Law
  162. Altmetric Badge
    Chapter 384 Pharmacotherapy of Alcohol Use Disorders
  163. Altmetric Badge
    Chapter 385 Tricyclics: Imipramine, Clomipramine, Trimipramine (Dibenzazepines)
  164. Altmetric Badge
    Chapter 386 Neuropsychopharmacotherapy: International Regulations and Regulating Laws in Japan
  165. Altmetric Badge
    Chapter 387 History of Antipsychotics
  166. Altmetric Badge
    Chapter 388 Use of Antipsychotics in the Treatment of Eating Disorders
  167. Altmetric Badge
    Chapter 389 Flupentixol in the Treatment of Psychosis
  168. Altmetric Badge
    Chapter 390 Asenapine in the Treatment of Psychosis
  169. Altmetric Badge
    Chapter 391 D-Serine in the Treatment of Psychosis
  170. Altmetric Badge
    Chapter 392 Evidence-Based Treatment with Antipsychotics in Schizophrenia: S3-Guideline and Current References
  171. Altmetric Badge
    Chapter 393 TCM Substances in Neuropsychopharmacotherapy
  172. Altmetric Badge
    Chapter 394 TCM Substances in Neuropsychopharmacotherapy: Basic Aspects with a Focus on Depression
  173. Altmetric Badge
    Chapter 395 Psychopharmacotherapy of PTSD
  174. Altmetric Badge
    Chapter 398 Nicotine Replacement Therapy
  175. Altmetric Badge
    Chapter 402 Lipid Metabolism Disturbances During Antipsychotic Treatment for Schizophrenia
  176. Altmetric Badge
    Chapter 403 International Comparison of ADHD Clinical Practice Guidelines: Comparing NICE, UMHS, and CADDRA Guidelines to Consider the Latest ADHD Practice
  177. Altmetric Badge
    Chapter 404 Ethics of Informed Consent: Coercive and Preventive Medication
  178. Altmetric Badge
    Chapter 405 Anxiolytics: Misuse, Dependence, and Withdrawal Syndromes
  179. Altmetric Badge
    Chapter 406 Tranquilizer/Anxiolytics: Benzodiazepines (Long-Acting) – Chlordiazepoxide, Clorazepate, Diazepam, Ethyl Loflazepate, Flutoprazepam, Medazepam, Mexazolam, Nitrazepam, Oxazolam
  180. Altmetric Badge
    Chapter 407 Tranquilizer/Anxiolytics: Benzodiazepines (Intermediate-Acting) – Alprazolam, Bromazepam, Clonazepam, Lorazepam
  181. Altmetric Badge
    Chapter 408 Tranquilizer/Anxiolytics: Benzodiazepines (Short-Acting) – Etizolam
  182. Altmetric Badge
    Chapter 410 Psychopharmacotherapy in Forensic Psychiatry
  183. Altmetric Badge
    Chapter 411 Delusion and Dopamine: Neuronal Insights in Psychotropic Drug Therapy
  184. Altmetric Badge
    Chapter 413 Serotonin Reuptake Inhibitors: Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, and Sertraline
  185. Altmetric Badge
    Chapter 414 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs): Venlafaxine, Desvenlafaxine, Duloxetine, Milnacipran, Levomilnacipran
  186. Altmetric Badge
    Chapter 415 Ziprasidone, Zuclopenthixole, and Fluspirilene in the Treatment of Psychosis
  187. Altmetric Badge
    Chapter 416 Low-Potency Antipsychotics: Levomepromazine, Melperon, and Pipamperone
  188. Altmetric Badge
    Chapter 417 First-Generation Antipsychotics as a Bridge to Second-Generation Antipsychotics in the Japanese Pharmaceutical Industry: Mosapramine, Timiperone, Zotepine, and Nemonapride
  189. Altmetric Badge
    Chapter 418 Acetylcholinesterase inhibitors (Galantamine, Rivastigmine, and Donepezil)
  190. Altmetric Badge
    Chapter 419 Nootropics (Piracetam, Pyritinol, Co-dergocrine, Meclophenoxat, Pentoxifylline, Nimodipine)
  191. Altmetric Badge
    Chapter 420 Ketamine in Psychiatric Disorders
  192. Altmetric Badge
    Chapter 421 Somnologics
  193. Altmetric Badge
    Chapter 422 Complementary Medications (Statins, Nicergoline, Naftidrofuryl) in Dementia
  194. Altmetric Badge
    Chapter 423 Amine Precursors in Depressive Disorders and the Blood-Brain Barrier
  195. Altmetric Badge
    Chapter 424 The Dopamine D 2 Receptor Partial Agonist Antipsychotics, Aripiprazole, and Brexpiprazole
  196. Altmetric Badge
    Chapter 425 Hallucinogens as Therapeutic Agents: Past, Present, and Future
  197. Altmetric Badge
    Chapter 427 Psychopharmacotherapy of Depressive Disorders
  198. Altmetric Badge
    Chapter 428 Pharmacotherapy of Alzheimer’s Disease (AD) and Behavioral and Psychological Symptoms of Dementia (BPSD) in Frail Older Patients
  199. Altmetric Badge
    Chapter 429 From Perospirone and Blonanserin to Lurasidone
  200. Altmetric Badge
    Chapter 430 Topiramate, Naltrexone, and Acamprosate in the Treatment of Alcohol Use Disorders
  201. Altmetric Badge
    Chapter 431 Psychopharmacotherapy of Pain
  202. Altmetric Badge
    Chapter 432 Hypnotics: Definition, Classifications, Indications, and Differential Indications
  203. Altmetric Badge
    Chapter 433 Psychopharmacotherapy of Obsessive-Compulsive and Related Disorders
  204. Altmetric Badge
    Chapter 434 Post-stroke Depression: Genetics, Mechanisms, and Treatment
  205. Altmetric Badge
    Chapter 435 Infantile Spasms: Pharmacotherapy Challenges
  206. Altmetric Badge
    Chapter 436 Nortriptyline and Maprotiline for Depressions
  207. Altmetric Badge
    Chapter 437 Combination Therapies and Switching of Agents in Depression and Bipolar Disorders
  208. Altmetric Badge
    Chapter 438 Pharmacotherapy of Alcohol Dependence: Treatment Readiness and Compliance Barriers
  209. Altmetric Badge
    Chapter 439 Pharmacotherapy of Psychosis in Parkinson’s Disease
  210. Altmetric Badge
    Chapter 440 Anti-convulsant Agents: Benzodiazepines (Clobazam, Clonazepam, Diazepam, Lorazepam, Midazolam)
  211. Altmetric Badge
    Chapter 441 Neuropsychopharmacotherapy: Aspects of Placebo Effects
  212. Altmetric Badge
    Chapter 442 Challenges of Parkinson’s Disease Care in Southeast Asia
  213. Altmetric Badge
    Chapter 444 Novel Pharmaceutical Approaches in Dementia
  214. Altmetric Badge
    Chapter 445 Antipsychotic Drug Prescription and Behavioral Problems in Individuals with Intellectual Disability
  215. Altmetric Badge
    Chapter 446 Augmentation of Psychotherapy with D-Cycloserine in Patients with Anxiety Disorders
  216. Altmetric Badge
    Chapter 447 Lithium in Psychiatric Indications
  217. Altmetric Badge
    Chapter 448 Neurochemical Mobile: A Heuristic Tool for Understanding Dynamic Complexity and Treatment of Alcohol Withdrawal
  218. Altmetric Badge
    Chapter 449 Anti-convulsant Agents: Lacosamide and Perampanel
  219. Altmetric Badge
    Chapter 451 Treatment of Sleep Disorders in Specific Psychiatric Diseases
  220. Altmetric Badge
    Chapter 453 Olanzapine in the Treatment of Psychosis
  221. Altmetric Badge
    Chapter 455 Hypnotics: Course and Duration of Therapy, Side Effects, Contraindications, Interactions, Withdrawal Syndromes, and Resistance to Therapy
  222. Altmetric Badge
    Chapter 456 Clinical Problems of Drugs Used to Treat Movement Disorders
  223. Altmetric Badge
    Chapter 457 Pharmacotherapy for Cocaine Use Disorders
  224. Altmetric Badge
    Chapter 458 Pharmacotherapy of Sleep Disorders During Pregnancy and Nursing
  225. Altmetric Badge
    Chapter 459 Ethnopharmacology and the Development of Psychoactive Drug: A Critical Overview
  226. Altmetric Badge
    Chapter 460 Therapy of Sleep Disorders in Parkinson’s Disease
  227. Altmetric Badge
    Chapter 461 The Endocannabinoid System in the Central Nervous System: Emphasis on the Role of the Mitochondrial Cannabinoid Receptor 1 (mtCB1R)
  228. Altmetric Badge
    Chapter 462 Recommendations from Current German, British, American, and Australian Guidelines on Alcohol Treatment
  229. Altmetric Badge
    Chapter 463 Management of Sexual Dysfunction in Neurodegenerative Diseases
  230. Altmetric Badge
    Chapter 465 Cannabinoid Drugs in Mental Health Disorders
  231. Altmetric Badge
    Chapter 466 Anti-convulsant Agents: Pharmacology and Biochemistry
  232. Altmetric Badge
    Chapter 467 Anti-convulsant Agents: Cannabidiol and Fenfluramine
  233. Altmetric Badge
    Chapter 468 Nalmefene in the Treatment of Alcohol Use Disorders
  234. Altmetric Badge
    Chapter 469 Anti-convulsant Agents: Cenobamate
  235. Altmetric Badge
    Chapter 470 D-Serine: Basic Aspects with a Focus on Psychosis
  236. Altmetric Badge
    Chapter 471 Quetiapine in the Treatment of Psychosis
  237. Altmetric Badge
    Chapter 472 Clozapine in the Treatment of Psychosis
  238. Altmetric Badge
    Chapter 473 Risperidone and Paliperone in the Treatment of Psychosis
  239. Altmetric Badge
    Chapter 474 Piperazine Phenothiazines: Fluphenazine and Perphenazine
Overall attention for this book and its chapters
Altmetric Badge

Mentioned by

twitter
3 X users
facebook
1 Facebook page
wikipedia
3 Wikipedia pages

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
32 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
NeuroPsychopharmacotherapy
Published by
Springer International Publishing, August 2022
DOI 10.1007/978-3-030-62059-2
ISBNs
978-3-03-062058-5, 978-3-03-062059-2
Editors

Riederer, Peter, Laux, Gerd, Nagatsu, Toshiharu, Le, Weidong, Riederer, Christian

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 3%
Unknown 31 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 4 13%
Student > Ph. D. Student 4 13%
Student > Bachelor 3 9%
Other 2 6%
Professor 1 3%
Other 2 6%
Unknown 16 50%
Readers by discipline Count As %
Chemical Engineering 4 13%
Medicine and Dentistry 3 9%
Pharmacology, Toxicology and Pharmaceutical Science 2 6%
Psychology 2 6%
Agricultural and Biological Sciences 1 3%
Other 3 9%
Unknown 17 53%